Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nab-paclitaxel + cisplatin + toripalimab
- Development stage
- Unknown
- Lead developer
- Junshi Biosciences
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
AP + Toripalimab is an investigational chemo-immunotherapy combination regimen being evaluated as induction therapy for patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC). The regimen consists of **toripalimab**, a humanized IgG4 monoclonal antibody that targets the Programmed Cell Death Protein-1 (PD-1) receptor, and the **AP chemotherapy regimen**, which comprises **nab-paclitaxel** (albumin-bound paclitaxel) and **cisplatin**. Toripalimab acts as an immune checkpoint inhibitor by blocking the PD-1/PD-L1 pathway, thereby restoring the anti-tumor activity of exhausted T-cells. Nab-paclitaxel is a microtubule inhibitor that causes cell cycle arrest, while cisplatin is a platinum-based alkylating agent that induces DNA cross-linking and apoptosis. This combination aims to enhance pathological response rates and improve surgical outcomes in the neoadjuvant setting.
- Brand names
- Tuoyi
- Other names
- Nab-Paclitaxel + Cisplatin + ToripalimabAP regimen + ToripalimabAP + Toripalimab
02
Targets
TUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)DNA
Beyond the preview
Go deeper on nab-paclitaxel + cisplatin + toripalimab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nab-paclitaxel + cisplatin + toripalimab.